n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
- PMID: 22686415
- DOI: 10.1056/NEJMoa1203859
n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia
Abstract
Background: The use of n-3 fatty acids may prevent cardiovascular events in patients with recent myocardial infarction or heart failure. Their effects in patients with (or at risk for) type 2 diabetes mellitus are unknown.
Methods: In this double-blind study with a 2-by-2 factorial design, we randomly assigned 12,536 patients who were at high risk for cardiovascular events and had impaired fasting glucose, impaired glucose tolerance, or diabetes to receive a 1-g capsule containing at least 900 mg (90% or more) of ethyl esters of n-3 fatty acids or placebo daily and to receive either insulin glargine or standard care. The primary outcome was death from cardiovascular causes. The results of the comparison between n-3 fatty acids and placebo are reported here.
Results: During a median follow up of 6.2 years, the incidence of the primary outcome was not significantly decreased among patients receiving n-3 fatty acids, as compared with those receiving placebo (574 patients [9.1%] vs. 581 patients [9.3%]; hazard ratio, 0.98; 95% confidence interval [CI], 0.87 to 1.10; P=0.72). The use of n-3 fatty acids also had no significant effect on the rates of major vascular events (1034 patients [16.5%] vs. 1017 patients [16.3%]; hazard ratio, 1.01; 95% CI, 0.93 to 1.10; P=0.81), death from any cause (951 [15.1%] vs. 964 [15.4%]; hazard ratio, 0.98; 95% CI, 0.89 to 1.07; P=0.63), or death from arrhythmia (288 [4.6%] vs. 259 [4.1%]; hazard ratio, 1.10; 95% CI, 0.93 to 1.30; P=0.26). Triglyceride levels were reduced by 14.5 mg per deciliter (0.16 mmol per liter) more among patients receiving n-3 fatty acids than among those receiving placebo (P<0.001), without a significant effect on other lipids. Adverse effects were similar in the two groups.
Conclusions: Daily supplementation with 1 g of n-3 fatty acids did not reduce the rate of cardiovascular events in patients at high risk for cardiovascular events. (Funded by Sanofi; ORIGIN ClinicalTrials.gov number, NCT00069784.).
Comment in
-
Diabetes: basal insulin and n-3 fatty acids--no effect on cardiovascular outcomes.Nat Rev Endocrinol. 2012 Jun 26;8(8):446. doi: 10.1038/nrendo.2012.111. Nat Rev Endocrinol. 2012. PMID: 22733269 No abstract available.
-
Diabetes: Does glycemic control reduce cardiovascular event rates?Nat Rev Cardiol. 2012 Jul 3;9(8):434. doi: 10.1038/nrcardio.2012.96. Nat Rev Cardiol. 2012. PMID: 22751264 No abstract available.
-
ACP Journal Club. Daily n-3 fatty acid supplements did not reduce CV events in high-risk patients with dysglycemia.Ann Intern Med. 2012 Sep 18;157(6):JC3-11. doi: 10.7326/0003-4819-157-6-201209180-02011. Ann Intern Med. 2012. PMID: 22986403 No abstract available.
-
n-3 fatty acids and cardiovascular outcomes in dysglycemia.N Engl J Med. 2012 Nov 1;367(18):1760; author reply 1761. doi: 10.1056/NEJMc1210552. N Engl J Med. 2012. PMID: 23113491 No abstract available.
-
n-3 fatty acids and cardiovascular outcomes in dysglycemia.N Engl J Med. 2012 Nov 1;367(18):1760-1; author reply 1761. doi: 10.1056/NEJMc1210552. N Engl J Med. 2012. PMID: 23113492 No abstract available.
-
N-3 fatty acids did not reduce major cardiovascular events in patients with dysglycaemia.Evid Based Med. 2013 Aug;18(4):e34. doi: 10.1136/eb-2012-101012. Epub 2012 Nov 21. Evid Based Med. 2013. PMID: 23173155 No abstract available.
Publication types
MeSH terms
Substances
Associated data
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical